Novaccess Global Inc. has signed a letter of intent and formed a partnership with BCN Biosciences LLC to expand its immunotherapy platform. Utilizing BCN’s small-molecule drug BCN-057, Novaccess Global has begun the development of a fourth generation of its novel brain tumor immunotherapy TLR-AD-1, targeting glioblastoma.
Colonization of the stomach by the bacterium Helicobacter pylori can cause gastric cancer by secreting the CagA oncoprotein. Now, a Japanese laboratory has discovered that CagA disrupted Wnt/PCP signaling and altered the polarity in which the squamous cells of the developing gastric epithelium are arranged, causing the hyperproliferation of the stem cells.
Shanghai Haiyan Pharmaceutical Technology Co. Ltd. and Yangtze River Pharmaceutical Group have synthesized macrophage colony-stimulating factor 1 receptor (CSF-1R; CD115; c-Fms) inhibitors reported to be useful for the treatment of cancer.
Krystal Biotech Inc. has received FDA acceptance of its IND application for lead oncology drug candidate KB-707 for the treatment of locally advanced or metastatic solid tumor malignancies. KB-707 is a modified herpes simplex virus 1 (HSV-1) vector designed to deliver genes encoding both human IL-12 and IL-2 to the tumor microenvironment and promote systemic immune-mediated tumor clearance.
A team of scientists led by The Wistar Institute has been awarded a 5-year National Cancer Institute (NCI) Program Project Grant valued at more than $12 million to explore the role of Epstein-Barr virus (EBV) in epithelial cancers. The project, which brings together scientists from The Wistar Institute and Harvard University, will focus entirely on the EBV-epithelial cancer link and look at metabolic and epigenetic vulnerabilities simultaneously.
Researchers from Chongqing Medical University have reported discovering a novel cyclin-dependent kinase 7 (CDK7) inhibitor, N76-1, which they are investigating as a potential new candidate for the treatment of triple-negative breast cancer (TNBC).
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase coupled to Wee1-like protein kinase (Wee1) targeting moiety via linker acting as Wee1 degradation inducers reported to be useful for the treatment of cancer.
Lynk Pharmaceuticals Co. Ltd. has disclosed nitrogen-containing heterocyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Nearly five years after submitting its first NDA seeking U.S. approval for Vanflyta (quizartinib) for treating a subset of patients with acute myeloid leukemia (AML), Daiichi Sankyo Co. Ltd. finally cleared the last hurdle. The FDA on July 20 approved the FLT3 inhibitor for use in combination with cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed disease that is FLT3 ITD-positive.
RSS
